1. Home
  2. IDAI vs ITRM Comparison

IDAI vs ITRM Comparison

Compare IDAI & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo T Stamp Inc.

IDAI

T Stamp Inc.

HOLD

Current Price

$3.72

Market Cap

20.9M

Sector

Technology

ML Signal

HOLD

Logo Iterum Therapeutics plc

ITRM

Iterum Therapeutics plc

HOLD

Current Price

$0.42

Market Cap

24.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDAI
ITRM
Founded
2016
2015
Country
United States
Ireland
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.9M
24.3M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
IDAI
ITRM
Price
$3.72
$0.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$12.00
$9.00
AVG Volume (30 Days)
158.6K
1.2M
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,727,824.00
$390,000.00
Revenue This Year
$3.46
N/A
Revenue Next Year
$219.85
$325.95
P/E Ratio
N/A
N/A
Revenue Growth
72.57
N/A
52 Week Low
$1.43
$0.36
52 Week High
$18.75
$2.18

Technical Indicators

Market Signals
Indicator
IDAI
ITRM
Relative Strength Index (RSI) 42.08 39.30
Support Level $4.00 $0.44
Resistance Level $4.57 $0.49
Average True Range (ATR) 0.34 0.04
MACD -0.05 0.01
Stochastic Oscillator 8.08 15.81

Price Performance

Historical Comparison
IDAI
ITRM

About IDAI T Stamp Inc.

T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: